Canaccord Genuity Maintains Beam Therapeutics at Buy, Raises Target to $79
Canaccord Genuity maintained its Buy rating and raised its price target to $79 from $78.
Related stories
Jakarta Stocks Fall 16.7% in October, Worst Since March 2020
M impact | EQUITY | Oct 30, 2026, 09:05 AM UTC
Erste Bank Polska Reports Third-Quarter Profit in Line With Expectations
Growing mortgage lending and resilient net interest income helped offset Poland’s bank tax hike, the bank said.
M impact | EQUITY | Oct 30, 2026, 09:04 AM UTC
European session market picture: S&P 500 -0.84%, Nasdaq 100 -1.95%; EUR/USD +0.15%, WTI +1.61%, LLOY leads volume
European session market picture. US index futures: S and P futures is down 0.84 percent, Nasdaq futures is down 1.95 percent, Dow futures is up 0.18 percent and Russell futures is
M impact | EQUITY | Oct 30, 2026, 09:01 AM UTC
AMD, Nvidia, Micron and Arm shares fall
AMD fell 6.5%, Nvidia 2.5%, Micron 3.7% and Arm 7.5%.
M impact | EQUITY | Oct 30, 2026, 08:59 AM UTC
BlackRock Raises Combined Stake in Tryg Above 5%
BlackRock's combined holding in Tryg has risen above 5%.
M impact | EQUITY | Oct 30, 2026, 08:59 AM UTC
Jiangxi Copper falls more than 6% again intraday
M impact | EQUITY | Oct 30, 2026, 08:57 AM UTC